• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

改良菲啶PJ34揭示了人类癌细胞中一种独特的细胞死亡机制。

The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells.

作者信息

Cohen-Armon Malka

机构信息

Sackler Faculty of Medicine, and Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv 69978, Israel.

出版信息

Cancers (Basel). 2020 Jun 19;12(6):1628. doi: 10.3390/cancers12061628.

DOI:10.3390/cancers12061628
PMID:32575437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7352794/
Abstract

This overview summarizes recent data disclosing the efficacy of the PARP inhibitor PJ34 in exclusive eradication of a variety of human cancer cells without impairing healthy proliferating cells. Its cytotoxic activity in cancer cells is attributed to the insertion of specific un-repairable anomalies in the structure of their mitotic spindle, leading to mitotic catastrophe cell death. This mechanism paves the way to a new concept of cancer therapy.

摘要

本综述总结了近期数据，这些数据揭示了PARP抑制剂PJ34在特异性根除多种人类癌细胞而不损害健康增殖细胞方面的功效。其在癌细胞中的细胞毒性活性归因于在其有丝分裂纺锤体结构中插入特定的不可修复异常，导致有丝分裂灾难细胞死亡。这一机制为癌症治疗的新概念铺平了道路。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e79/7352794/45c7fc5afbd5/cancers-12-01628-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e79/7352794/0dcdda74949b/cancers-12-01628-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e79/7352794/f673606974ba/cancers-12-01628-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e79/7352794/45c7fc5afbd5/cancers-12-01628-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e79/7352794/0dcdda74949b/cancers-12-01628-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e79/7352794/f673606974ba/cancers-12-01628-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e79/7352794/45c7fc5afbd5/cancers-12-01628-g003.jpg

相似文献

1
The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells.改良菲啶PJ34揭示了人类癌细胞中一种独特的细胞死亡机制。
Cancers (Basel). 2020 Jun 19;12(6):1628. doi: 10.3390/cancers12061628.
2
Exclusive modifications of NuMA in malignant epithelial cells: A potential therapeutic mechanism.恶性上皮细胞中NuMA的特异性修饰：一种潜在的治疗机制。
Drug Discov Today. 2022 May;27(5):1205-1209. doi: 10.1016/j.drudis.2022.02.002. Epub 2022 Feb 7.
3
The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts.菲衍生物PJ34能特异性消除异种移植模型中的人胰腺癌细胞。
Oncotarget. 2019 Oct 22;10(58):6269-6282. doi: 10.18632/oncotarget.27268.
4
PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.PJ34是一种PARP - 1抑制剂，可抑制肝癌细胞的生长并增强顺铂的抑制作用。
Oncol Rep. 2008 Sep;20(3):567-72.
5
3-Aminobenzamide protects primary human keratinocytes from UV-induced cell death by a poly(ADP-ribosyl)ation independent mechanism.3-氨基苯甲酰胺通过一种不依赖多聚（ADP-核糖基）化的机制保护原代人角质形成细胞免受紫外线诱导的细胞死亡。
Biochim Biophys Acta. 2013 Mar;1833(3):743-51. doi: 10.1016/j.bbamcr.2012.12.003. Epub 2012 Dec 12.
6
Effects of PARP-1 inhibitor and ERK inhibitor on epithelial mesenchymal transitions of the ovarian cancer SKOV3 cells.PARP-1抑制剂和ERK抑制剂对卵巢癌SKOV3细胞上皮间质转化的影响。
Pharmacol Rep. 2016 Dec;68(6):1225-1229. doi: 10.1016/j.pharep.2016.08.001. Epub 2016 Aug 2.
7
Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.PARP-1抑制剂PJ34与HDAC抑制剂SAHA对肝癌细胞增殖的协同抑制作用
J Huazhong Univ Sci Technolog Med Sci. 2015 Aug;35(4):535-540. doi: 10.1007/s11596-015-1466-6. Epub 2015 Jul 31.
8
Inhibition of proliferation and invasiveness of ovarian cancer C13* cells by a poly(ADP-ribose) polymerase inhibitor and the role of nuclear factor-κB.聚（ADP-核糖）聚合酶抑制剂对卵巢癌C13*细胞增殖和侵袭的抑制作用及核因子-κB的作用
J Int Med Res. 2013 Oct;41(5):1577-85. doi: 10.1177/0300060513480913.
9
Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells.Polo样激酶1抑制剂BI2536在非小细胞肺癌细胞中激活纺锤体组装检查点后导致有丝分裂灾难。
Cancer Lett. 2015 Feb 28;357(2):591-601. doi: 10.1016/j.canlet.2014.12.023. Epub 2014 Dec 15.
10
Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.聚（ADP-核糖）聚合酶抑制剂增强 131I-间碘苄胍/拓扑替康联合治疗表达去甲肾上腺素转运体的细胞和异种移植物的毒性。
J Nucl Med. 2012 Jul;53(7):1146-54. doi: 10.2967/jnumed.111.095943. Epub 2012 Jun 11.

引用本文的文献

1
Mitochondria as Regulators of Nonapoptotic Cell Death in Cancer.线粒体作为癌症中非凋亡性细胞死亡的调节因子。
MedComm (2020). 2025 Jul 23;6(8):e70244. doi: 10.1002/mco2.70244. eCollection 2025 Aug.
2
The post-translational modification of NuMA in cancer cells is a new target for cancer eradication.癌细胞中核有丝分裂器蛋白（NuMA）的翻译后修饰是根除癌症的新靶点。
Cell Death Dis. 2025 Jul 18;16(1):536. doi: 10.1038/s41419-025-07868-7.
3
Liquid‒liquid phase separation and poly(ADP‒ribosyl)ation in the context of ultraviolet radiation-induced stress in mammalian cells.

本文引用的文献

1
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.乳腺癌细胞对PARP抑制剂的反应与BRCA状态无关。
J Clin Med. 2020 Mar 30;9(4):940. doi: 10.3390/jcm9040940.
2
The kinase polypharmacology landscape of clinical PARP inhibitors.临床 PARP 抑制剂的激酶多靶性药理学特征。
Sci Rep. 2020 Feb 17;10(1):2585. doi: 10.1038/s41598-020-59074-4.
3
PARP and PARG inhibitors in cancer treatment.聚腺苷二磷酸核糖聚合酶（PARP）和聚腺苷二磷酸核糖水解酶（PARG）抑制剂在癌症治疗中的应用。
哺乳动物细胞紫外线辐射诱导应激背景下的液-液相分离与聚（ADP-核糖）化
Biophys Rev. 2025 Mar 11;17(2):499-510. doi: 10.1007/s12551-025-01294-x. eCollection 2025 Apr.
4
Synthesis of Thiaphenanthridinones from Sulfinate Esters and 2-Borylanilines.由亚磺酸酯和2-硼基苯胺合成噻吩并菲啶酮
Org Lett. 2024 Nov 15;26(45):9676-9681. doi: 10.1021/acs.orglett.4c03420. Epub 2024 Nov 6.
5
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions.聚（ADP-核糖）聚合酶（PARP）抑制剂在癌症治疗中的应用：进展、挑战与未来方向。
Biomolecules. 2024 Oct 9;14(10):1269. doi: 10.3390/biom14101269.
6
Non-rodent Models of Atherosclerosis: Repurposing of Existing Drugs and Search for Novel Treatment Strategies.动脉粥样硬化的非啮齿动物模型：现有药物的重新利用及新型治疗策略的探索
Curr Cardiol Rev. 2025;21(1):e1573403X316529. doi: 10.2174/011573403X316529240919103119.
7
Visible light-induced Mallory reaction of tertiary benzanilides iminium intermediates.可见光诱导的叔苯甲酰亚胺鎓中间体的马洛里反应。
Chem Sci. 2024 Sep 19;15(41):17210-6. doi: 10.1039/d4sc03907f.
8
SARS-CoV-2 N protein-induced Dicer, XPO5, SRSF3, and hnRNPA3 downregulation causes pneumonia.SARS-CoV-2 N 蛋白诱导的 Dicer、XPO5、SRSF3 和 hnRNPA3 下调导致肺炎。
Nat Commun. 2024 Aug 13;15(1):6964. doi: 10.1038/s41467-024-51192-1.
9
PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages.慢性炎症中的聚（ADP-核糖）聚合酶与ADP-核糖基化：聚焦巨噬细胞
Pathogens. 2023 Jul 23;12(7):964. doi: 10.3390/pathogens12070964.
10
PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer.聚（ADP-核糖）聚合酶、聚（ADP-核糖）及烟酰胺腺嘌呤二核苷酸代谢及其在癌症中的抑制剂
Cancers (Basel). 2020 Nov 24;12(12):3494. doi: 10.3390/cancers12123494.
Genes Dev. 2020 Mar 1;34(5-6):360-394. doi: 10.1101/gad.334516.119. Epub 2020 Feb 6.
4
The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts.菲衍生物PJ34能特异性消除异种移植模型中的人胰腺癌细胞。
Oncotarget. 2019 Oct 22;10(58):6269-6282. doi: 10.18632/oncotarget.27268.
5
Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G DNA Damage Checkpoint.ATM 和 PARP1 抑制的协同作用涉及 DNA 损伤和消除 G 期 DNA 损伤检查点。
Mol Cancer Ther. 2020 Jan;19(1):123-134. doi: 10.1158/1535-7163.MCT-19-0474. Epub 2019 Oct 9.
6
PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells.聚（ADP-核糖）聚合酶（PARP）抑制剂PJ34可保护线粒体，并与顺铂或替莫唑胺联合诱导B16F10黑色素瘤细胞发生DNA损伤介导的凋亡。
Front Physiol. 2019 May 7;10:538. doi: 10.3389/fphys.2019.00538. eCollection 2019.
7
Signal-induced PARP1-Erk synergism mediates IEG expression.信号诱导的 PARP1-Erk 协同作用介导 IEG 表达。
Signal Transduct Target Ther. 2019 Apr 12;4:8. doi: 10.1038/s41392-019-0042-0. eCollection 2019.
8
Poly(ADP-ribosyl)ation of OVOL2 regulates aneuploidy and cell death in cancer cells.OVOL2 的聚（ADP-核糖）化调节癌细胞的非整倍体和细胞死亡。
Oncogene. 2019 Apr;38(15):2750-2766. doi: 10.1038/s41388-018-0615-3. Epub 2018 Dec 12.
9
Inhibition of CPAP-tubulin interaction prevents proliferation of centrosome-amplified cancer cells.抑制 CPAP-微管蛋白相互作用可阻止中心体扩增癌细胞的增殖。
EMBO J. 2019 Jan 15;38(2). doi: 10.15252/embj.201899876. Epub 2018 Dec 10.
10
The Cellular Response to Transcription-Blocking DNA Damage.细胞对转录阻断型 DNA 损伤的反应。
Trends Biochem Sci. 2018 May;43(5):327-341. doi: 10.1016/j.tibs.2018.02.010.